2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues.
Stay tuned in 2017 for more of the same!
INTERVIEWS OF THE YEAR
Actelion’s Dr. Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period of rapid growth.
Olivier Laureau on how Servier´s growth depends on investment in R&D and a strong international footprint; and how their ambition is to grow from total revenues of four billion Euros today, to five billion Euros over the next five years.
Giles Platford talks Takeda’s focus on emerging markets – one of three key growth drivers for the company – and the role of pharmaceutical innovators in bridging access to potentially life-saving therapies.
Novo Nordisk’s Maziar Mike Doustdar explains the significance of the 141 countries in the company’s IO region to global operations and the varying strategies for success in these geographies.
The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player around the world.
MOST DOWNLOADED REPORTS
MOST READ ARTICLES
Switzerland’s pharma and life science hotspots do not begin and end with Basel. Zurich, Geneva, and Zug are all now staking serious claims for global recognition.
Digital innovations currently being rolled out and integrated across Europe threaten to re-sculpt the healthcare industry as we know it.
Although Mexico is moving in the right direction with regards to universal healthcare coverage, a number of barriers to effective implementation remain.